GlassScriptPhysician profile
Alan R Trumbly
NPI 1417121286
$6,092.56
in general payments reported to CMS, 2019-2025
62 companies · $1,978 in 2025
The $1,978 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,295 · 2020: $426 · 2021: $90.81 · 2022: $644 · 2023: $812 · 2024: $847 · 2025: $1,978.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,162 · Long Term Medical Supply Or Device Loan: $1,396 · Education: $79.02.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,162.36 |
| Long Term Medical Supply Or Device Loan | $1,395.80 |
| Education | $79.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,723.07 | 2019-2025 | |
| Novocure INC. | $734.19 | 2019-2025 | Optune, Optune Gio |
| Janssen Biotech, INC. | $330.53 | 2019-2025 | Rybrevant |
| Astrazeneca Pharmaceuticals LP | $269.14 | 2019-2025 | Imfinzi, Andexxa, Enhertu |
| Pfizer INC. | $205.83 | 2019-2025 | |
| Genzyme Corporation | $193.30 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $165.48 | 2019-2025 | Opdivo |
| Davol INC. | $135.62 | 2019 | |
| Gilead Sciences, INC. | $135.43 | 2019-2025 | Trodelvy |
| Merck Sharp & Dohme LLC | $130.04 | 2019-2023 | Keytruda |
| Sobi, INC | $128.19 | 2022-2025 | |
| Celgene Corporation | $118.80 | 2019-2023 | Reblozyl, Pomalyst, Opdualag |
| Sirtex Medical INC | $118.17 | 2019-2024 | Sir-Spheres Microspheres |
| Genentech USA, INC. | $101.04 | 2019-2020 | |
| Pharmaessentia USA Corporation | $99.70 | 2024-2025 | Besremi |
Show all 61 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alan Trumbly listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.